ITS’ Pan-Strain Influenza A T-Cell Vaccine Shows Promise In Elderly
This article was originally published in The Pink Sheet Daily
Executive Summary
U.K.-based Immune Targeting Systems reports promising Phase IIa results for its T-cell flu vaccine in recipients ages 65 to 74. Company looks to secure a partner before it moves into Phase III field trial.